var data={"title":"Brigatinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Brigatinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/810302?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=brigatinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Brigatinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50081297\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alunbrig</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50026689\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anaplastic Lymphoma Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131874\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-small cell lung cancer, metastatic (ALK-positive):</b> Oral: 90 mg once daily for 7 days; if tolerated, increase dose to 180 mg once daily; continue until disease progression or unacceptable toxicity (Kim 2017). <b>Note:</b> If therapy is interrupted for &ge;14 days due to reasons other than toxicity, resume treatment at 90 mg once daily for 7 days before escalating dose to the previously tolerated dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed dose:</i> If a dose is missed or vomited, do not administer an additional dose; take the next dose at the regularly scheduled time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage adjustment for concomitant strong CYP3A inhibitors:</b></i> Avoid concomitant use of strong CYP3A inhibitors; if concurrent therapy cannot be avoided, reduce the brigatinib dose by approximately 50% (eg, from 180 mg once daily to 90 mg once daily, or from 90 mg once daily to 60 mg once daily). After the strong CYP3A inhibitor is discontinued, resume brigatinib dose that was tolerated prior to initiation of the strong CYP3A inhibitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131875\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131882\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 to 89 mL/minute: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131883\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild (total bilirubin within ULN and AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN and any AST) impairment: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate (total bilirubin &gt;1.5 to 3 times ULN and any AST) or severe (total bilirubin &gt;3 times ULN and any AST) impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131884\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Once the dose is reduced for toxicity, do not subsequently escalate the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recommended brigatinib dosage adjustment levels:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If the dose received was 90 mg once daily:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First dose reduction: 60 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose reduction: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If the dose received was 180 mg once daily:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First dose reduction: 120 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose reduction: 90 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Third dose reduction: 60 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Permanently discontinue if unable to tolerate the 60 mg once daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Cardiac toxicity:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypertension:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 (systolic blood pressure [SBP] &ge;160 mm Hg or diastolic blood pressure [DBP] &ge;100 mm Hg, medical intervention indicated, &gt;1 antihypertensive medication necessary, or more intensive therapy than previously used): Interrupt brigatinib until hypertension improves to &le; grade 1 (SBP &lt;140 mm Hg and DBP &lt;90 mm Hg), then resume at the next lower dose. If grade 3 hypertension recurs, interrupt brigatinib until improvement to &le; grade 1 and resume at the next lower dose <b>or</b> permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 4 (life-threatening, urgent intervention required): Interrupt brigatinib until improvement to &le; grade 1, then resume at the next lower dose <b>or</b> permanently discontinue. If grade 4 hypertension recurs, permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bradycardia (heart rate &lt;60 bpm):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Symptomatic bradycardia: Interrupt brigatinib until recovery to asymptomatic bradycardia or to a resting heart rate of &ge;60 bpm. If a concomitant bradycardia-inducing medication is identified and discontinued (or dose-adjusted), upon recovery to asymptomatic bradycardia or to a resting heart rate of &ge;60 bpm, resume brigatinib at the previous dose. If no concomitant medication is identified (or cannot be discontinued or dose-adjusted), upon recovery to asymptomatic bradycardia or to a resting heart rate of &ge;60 bpm, resume brigatinib at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Life-threatening bradycardia (urgent intervention required): Permanently discontinue brigatinib if no contributing concomitant medication is identified. If contributing concomitant medication is present and discontinued (or dose-adjusted), upon recovery to asymptomatic bradycardia or to a resting heart rate of &ge;60 bpm, resume brigatinib at the next lower dose (with frequent monitoring). If life-threatening bradycardia recurs, permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Creatine phosphokinase (CPK) elevation:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 (CPK &gt;5 times ULN): Interrupt brigatinib therapy until improvement to &le; grade 1 (&le;2.5 times ULN) or to baseline, then resume at the previous dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 (CPK &gt;10 times ULN) or recurrent grade 3 toxicity: Interrupt brigatinib therapy until improvement to &le; grade 1 (&le;2.5 times ULN) or to baseline, then resume at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Hyperglycemia:</b></i> Grade 3 or higher (glucose &ge;250 mg/dL or 13.9 mmol/L): Interrupt brigatinib therapy if adequate hyperglycemic control cannot be achieved with optimal medical management. Once hyperglycemic control is achieved, consider dose reduction to the next lower dose or permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Lipase/amylase elevation:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 (&gt;2 times ULN): Interrupt brigatinib until improvement to &le; grade 1 (&le;1.5 times ULN) or to baseline, then resume at the previous dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 (&gt;5 times ULN) or recurrent grade 3 toxicity: Interrupt brigatinib therapy until improvement to &le; grade 1 (&le;1.5 times ULN) or to baseline, then resume at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Ocular toxicity:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2 or 3 visual disturbance: Interrupt brigatinib therapy until improvement to grade 1 or baseline, then resume at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 visual disturbance: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Pulmonary toxicity (interstitial lung disease [ILD]/pneumonitis):</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1: If new pulmonary symptoms develop during the first 7 days of therapy, interrupt brigatinib until improvement to baseline, then resume treatment at the same dose; do not escalate to 180 mg once daily if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of therapy, interrupt brigatinib until improvement to baseline, then resume at the previous dose. If ILD/pneumonitis recurs, permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2: If new pulmonary symptoms develop during the first 7 days of therapy, interrupt brigatinib until improvement to baseline, then resume treatment at the next lower dose; do not escalate to 180 mg once daily if ILD/pneumonitis is suspected. If new pulmonary symptoms occur after the first 7 days of therapy, interrupt brigatinib until improvement to baseline. If ILD/pneumonitis is suspected, resume at the next lower dose; otherwise, resume at the previous dose. If ILD/pneumonitis recurs, permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or 4: Permanently discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other toxicities:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3: Interrupt brigatinib therapy until improvement to baseline, then resume at the previous dose. If grade 3 toxicity recurs, interrupt brigatinib until improvement to baseline and then resume at the next lower dose <b>or</b> discontinue.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4: First occurrence: Interrupt brigatinib therapy until recovery to baseline and resume at the next lower dose <b>or</b> permanently discontinue. If grade 4 toxicity recurs, permanently discontinue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50081298\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alunbrig: 30 mg, 90 mg, 180 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alunbrig: 90 mg (7s) &amp; 180 mg (23s) (30 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50081296\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131892\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer orally with or without food. Swallow tablets whole; do not crush or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131850\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Brigatinib may cause reproductive toxicity, teratogenicity, and/or has a structural/toxicity profile similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50026691\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Non-small cell lung cancer, metastatic:</b> Treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on or are intolerant to crizotinib</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50117850\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Brigatinib may be confused with alectinib, bosutinib, ceritinib, crizotinib.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High-alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50103409\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (11% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (29% to 36%), headache (27% to 28%), peripheral neuropathy (13%, grades 3/4: &le;2%), insomnia (7% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (15% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum AST (38% to 65%), hyperglycemia (38% to 49%; including exacerbations), increased serum ALT (34% to 40%), increased amylase (27% to 39%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Increased serum lipase (21% to 45%), nausea (33% to 40%), diarrhea (19% to 38%), vomiting (23% to 24%), decreased appetite (15% to 22%), constipation (15% to 19%), abdominal pain (10% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (23% to 40%; grades 3/4: &lt;1%), lymphocytopenia (19% to 27%; grades 3/4: 3% to 5%), abnormal phosphorus levels (decreased; 15% to 23%; grades 3/4: &lt;1%), prolonged partial thromboplastin time (20% to 22%; grades 3/4: &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (15% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (27% to 48%), muscle spasm (12% to 17%), back pain (10% to 15%), myalgia (9% to 15%), arthralgia (14%), limb pain (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (18% to 34%), dyspnea (21% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (6% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (7% to 10%; including blurred vision, diplopia, and reduced visual acuity)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Interstitial pneumonitis (&le;9%), pneumonitis ( &le;9%), hypoxia (&le;3%), pneumonia (5% to 10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50026692\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50125081\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac effects: Hypertension was reported in ~10% to 20% of patients receiving brigatinib (including grade 3 hypertension). Blood pressure should be controlled prior to initiating brigatinib therapy. Monitor blood pressure after 2 weeks and at least monthly subsequently. May require brigatinib therapy interruption, dose reduction, or permanent discontinuation; may also require antihypertensive therapy. Bradycardia has also occurred with brigatinib therapy; monitor heart rate (more frequently if on concomitant bradycardia-inducing medication). Symptomatic bradycardia may require therapy interruption or dose reduction. Permanently discontinue for life-threatening bradycardia that is not associated with a concomitant medication. Use caution when administering brigatinib in combination with antihypertensive medications that cause bradycardia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Creatine phosphokinase (CPK) elevation: CPK elevations have been reported in up to 50% of patients receiving brigatinib (including grade 3 or 4 elevations). A higher incidence was associated with the 180 mg/day dose (compared to 90 mg/day). Monitor CPK levels during treatment; advise patients to report unexplained muscle pain, tenderness, or weakness. Elevated CPK levels may require therapy interruption or dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Pancreatic enzyme elevations (lipase and amylase) have been reported, including grade 3 or 4 elevations. A higher incidence was associated with the 180 mg/day dose (compared to 90 mg/day). Monitor amylase/lipase during treatment. May require therapy interruption or dose reduction. Nausea, vomiting, diarrhea, constipation, and abdominal pain have also been observed with brigatinib therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: More than 40% of patients receiving brigatinib experienced new or worsening hyperglycemia, including grade 3 toxicity. Some patients with diabetes or glucose intolerance (at baseline) required insulin therapy while receiving brigatinib. Monitor fasting serum glucose at baseline and periodically during treatment. Initiate or optimize antihyperglycemic therapy; if adequate serum glucose control cannot be achieved with optimal medical management, interrupt brigatinib until metabolic control is achieved. Dose reduction or permanent discontinuation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular toxicity: Visual disturbances such as blurred vision, diplopia, and reduced visual acuity have been reported. Grade 3 macular edema and cataract also occurred (rare). Advise patients to report visual symptoms. Interrupt brigatinib therapy and obtain an ophthalmologic evaluation in patients with new or worsening &ge; grade 2 visual symptoms. May require dose reduction or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Severe, life-threatening, and fatal cases of pulmonary toxicity consistent with interstitial lung disease (ILD)/pneumonitis have been reported. ILD/pneumonitis occurred early (within 9 days of brigatinib initiation; median onset: 2 days) in some patients. A higher incidence was associated with the 180 mg/day dose (compared to 90 mg/day). Monitor for new or worsening pulmonary symptoms (eg, dyspnea, cough), particularly in the first week of therapy. Interrupt brigatinib in any patient with new or worsening respiratory symptoms; promptly evaluate for ILD/pneumonitis or other potential cause of toxicity (eg, pulmonary embolism, tumor progression, or infectious etiology). May require dose reduction or permanent discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaplastic lymphoma kinase testing: Approved for use only in patients with metastatic non-small cell lung cancer (NSCLC) who test positive for the abnormal anaplastic lymphoma kinase (ALK) gene.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50101794\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP2C8 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50101791\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=112993&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Brigatinib may diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Brigatinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Brigatinib. Management: Avoid concurrent use of brigatinib with strong CYP3A4 inhibitors when possible. If combination cannot be avoided, reduce the brigatinib dose by approximately 50%, rounding to the nearest tablet strength (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Brigatinib may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Brigatinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Brigatinib may decrease the serum concentration of Progestins (Contraceptive).  Management: Females of childbearing potential should use an alternative, non-hormonal contraceptive during brigatinib therapy and for at least 4 months after the final brigatinib dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Brigatinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131849\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase serum brigatinib levels. Management: Avoid grapefruit and grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50125079\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, brigatinib may be expected to cause fetal harm if used in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women of reproductive potential should use an effective nonhormonal contraceptive during therapy and for at least 4 months after the last dose. Males with female partners of reproductive potential should use effective contraception during therapy and for at least 3 months after the last dose. Based on animal data, fertility in males may be reduced.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50125080\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if brigatinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy or for 1 week after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131891\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit and grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131894\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ALK positivity; monitor creatine phosphokinase (CPK) and amylase/lipase levels periodically throughout therapy; fasting serum glucose at baseline and periodically thereafter; monitor heart rate and blood pressure (after 2 weeks and at least monthly thereafter); monitor for signs/symptoms of interstitial lung disease (ILD)/pneumonitis (new or worsening pulmonary symptoms), muscular symptoms of CPK elevations, and visual disturbances (obtain ophthalmologic evaluation in patients with new or worsening &ge; grade 2 visual symptoms). Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131852\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Brigatinib is a broad spectrum multikinase inhibitor with activity against anaplastic lymphoma kinase (ALK), ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3, as well as EGFR deletion and point mutations. ALK autophosphorylation and ALK-mediated phosphorylation of downstream signaling proteins STAT3, AKT, ERK1/2, and S6 are inhibited by brigatinib. In vitro, brigatinib also inhibited proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins. Brigatinib has activity against cells expressing EML4-ALK and 17 mutant forms associated with ALK inhibitor resistance, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. Clinically, brigatinib showed anti-tumor activity against EML4-ALK mutant forms (including G1202R and L1196M) which were identified in NSCLC cells in patients who progressed on crizotinib.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50131853\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 153 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 66% bound to plasma proteins (not concentration dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic via CYP2C8 and CYP3A4; N-demethylation and cysteine conjugation are the two major metabolic pathways; metabolite AP26123 inhibits ALK with ~3-fold lower potency than brigatinib (in vitro)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (65%; 41% as unchanged drug); urine (25%; 86% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50170424\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Alunbrig Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 &amp; 180 mg (30): $17,100.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Alunbrig Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (30): $5,700.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (7): $3,990.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $17,100.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alunbrig (brigatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial [published online ahead of print]. <i>J Clin Oncol</i>. 2017;JCO2016715904. doi: 10.1200/JCO.2016.71.5904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/brigatinib-drug-information/abstract-text/28475456/pubmed\" target=\"_blank\" id=\"28475456\">28475456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed May 2, 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 112993 Version 22.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50081297\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50026689\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50131874\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50131875\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50131882\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50131883\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F50131884\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50081298\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50081296\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50131892\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F50131850\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50026691\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50117850\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50103409\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50026692\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50125081\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50101794\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50101791\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F50131849\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50125079\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50125080\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F50131891\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50131894\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50131852\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50131853\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50170424\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/112993|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=brigatinib-patient-drug-information\" class=\"drug drug_patient\">Brigatinib: Patient drug information</a></li></ul></div></div>","javascript":null}